Novo Nordisk | NVO - Current Liabilities



Novo Nordisk reported DKK236.12B in Current Liabilities for its fiscal quarter ending in March of 2025.


Current Liabilities Change Date
ANI Pharmaceuticals USD 236.83M 35.02M Jun/2025
Aurora Cannabis CAD 156.88M 7.07M Jun/2025
Bausch Health Companies USD 4.98B 719M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Canopy Growth CAD 98.67M 1.65M Jun/2025
Corcept Therapeutics USD 144.66M 1.6M Jun/2025
Drreddys Laboratories INR 142.59B 10.64B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
GlaxoSmithKline GBP 20.38B 453M Jun/2025
Merck USD 26.04B 863M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Novo Nordisk 207.52B 28.6B Jun/2025
Novo Nordisk DKK 236.12B 27.76B Mar/2025
Pacira USD 313.16M 1.57M Jun/2025
Perrigo USD 1.13B 52.3M Jun/2025
Prestige Brands USD 109.67M 3.04M Jun/2025
Sanofi 29.06B 3.16B Jun/2025
Supernus Pharmaceuticals USD 286.36M 4.59M Jun/2025
Zoetis USD 3.37B 19M Jun/2025